Extrait

To compare the clinical efficacy (i.e. radiological progression free survival [PFS]) of tasquinimod maintenance therapy with placebo in patients with metastatic castrate-resistant prostate cancer (mCRPC) who have not progressed after a first line docetaxel based chemotherapy.

Critère d'inclusion

• Maintenance therapy in metastatic Castrate Resistant Prostate Cancer patients who are not progressing under/after a first line docetaxel based chemotherapy

Liens

• ictrp
• euctr
• ictrp
• euctr
• euctr
• euctr
• ictrp
• euctr
• euctr
• euctr
• ictrp
• euctr
• ictrp
• ictrp
• ictrp
• ictrp
• ictrp
• euctr
• ictrp
• euctr